/

Sociétés

La

Non vérifié

Laminar Pharmaceuticals, S.A.

Ce que nous écrivons

BiologieÉcologie/Santé environnementaleFitness/Bien-êtreIndustrie pharmaceutiqueSanté Publique

3 communiqués de presse

Voir tous les communiqués de presse

Press Release cover image

24/07/2026

Santé

Fitness/Bien-être

Médecine - Divers

Écologie/Santé environnementale

Agriculture

Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

Source

Laminar Pharmaceuticals, S.A.

Émetteur

1.00

0

05/03/2025

Industrie pharmaceutique

Santé Publique

Biologie

Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients

Source

Laminar Pharmaceuticals, S.A.

Émetteur

1.00

0

Press Release cover image

11/06/2024

Industrie pharmaceutique

Santé Publique

Last patient in: Laminar Pharmaceuticals S.A. completes recruitment for CLINGLIO, the phase 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed glioblastoma

Source

Laminar Pharmaceuticals, S.A.

Émetteur

1.00

0

Followers

0

Compatibilité

0